Stryker Corporation (SYK) Earnings Call Transcripts

Stryker Corporation's Latest Earnings Call - Q3 FY2026

In the third quarter of 2026, Stryker Corporation reported organic sales growth of 7.7%, driven by strong performances in MedSurg and Neurotechnology, which grew 9.1%. However, the company acknowledged challenges in its hip and knee segments, leading to a revision of its full-year organic net sales growth guidance to 6.5% to 7%. Adjusted earnings per share were $3.52, reflecting a 10.3% increase year-over-year, but management expressed concerns about market conditions and operational distractions impacting future performance.

Reported metrics

Guidance from management

Management expects to maintain a similar overall organic growth rate in Q4 as achieved in Q3, with full-year organic net sales growth guidance revised to 6.5% to 7%. Adjusted EPS guidance is set at $14.80 to $14.90.

What management said

Yes, Joanne, I would just point you back to what we said a year ago, again, in terms of what we think our Ranger is across all of our businesses. I mean we're not going to obviously put detailed business by business. But if we look at just that overall [indiscernible] and then think about this new kind of reality that we're living within the hip and knee market, and that probably takes a little bit of a tick down. An...

Ryan, this is Nick. I'll take that from a capital perspective. So really, there's 2 components there. There's the demand side of the capital equation, and then there's us executing on mind. From a demand perspective, the order book remains strong and elevated. And of course, there's nuances by business, but by and large, the capital environment remains healthy. What we're focused on is continuing to execute on that d...

What analysts pressed on

Analysts expressed concerns about the slowdown in the hip and knee markets, questioning management on the potential for recovery and the impact of operational distractions on future performance. There were also inquiries about pricing pressures and competition in the orthopedic segment.

Main topics on the call

• Organic Sales Growth — Stryker achieved organic sales growth of 7.7% in Q3, with MedSurg and Neurotechnology leading at 9.1%. However, management noted that 'overall results fell short of our expectations' due to challenges in the hip and knee...
• Challenges in Hip and Knee Markets — Management highlighted a slowdown in the hip and knee market, citing 'affordability concerns from higher insurance premiums' and 'increased preauthorization denials' as key factors. They estimated market growth in this s...
• Guidance Revision — Stryker revised its full-year organic net sales growth guidance to 6.5% to 7%, down from previous expectations due to 'softer hip and knee procedure trends.' Adjusted EPS guidance was updated to $14.80 to $14.90.
• Strong Performance in MedSurg and Neurotechnology — The MedSurg and Neurotechnology segments performed well, with organic sales growth of 9.1%. Management noted 'double-digit performances' in Endoscopy and OrthoTec divisions, indicating strong demand in these areas.

Read the full Stryker Corporation transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 53 Stryker Corporation earnings call transcripts on record, spanning January 28, 2020 to October 29, 2026. Based on this history, Stryker Corporation reports quarterly. The most recent call on file is dated October 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SYK

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

53

First call

January 28, 2020

Most recent

October 29, 2026

Reporting cadence

quarterly